We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
BioTrove Combines Forces with OSI Pharmaceuticals to Enable Lead Discovery
News

BioTrove Combines Forces with OSI Pharmaceuticals to Enable Lead Discovery

BioTrove Combines Forces with OSI Pharmaceuticals to Enable Lead Discovery
News

BioTrove Combines Forces with OSI Pharmaceuticals to Enable Lead Discovery

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "BioTrove Combines Forces with OSI Pharmaceuticals to Enable Lead Discovery"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

BioTrove, Inc. has announced a new, non-exclusive marketing agreement with OSI Pharmaceuticals, Inc. to provide clients with a complete solution for lead compound discovery.

Combining OSI Pharmaceuticals’ Integrated Lead Discovery Platform with BioTrove’s RapidFire™ mass spectrometry-based assay development, screening and analysis services, the agreement will enable customers to pursue challenging drug targets in an accurate, efficient and cost-effective manner, BioTrove says.

“The collaboration addresses a critical, unmet need for companies in the biopharmaceutical industry, especially those without access to compound libraries or screening infrastructure,” said Albert A. Luderer, Ph.D., President and CEO, BioTrove. “Our joint solution with OSI will enable increased research around novel targets for companies who may have crucial insights about disease progression, but do not specialize in large-scale high-throughput screening internally.”

The companies’ complete lead discovery service will provide access to OSI Pharmaceuticals’ Integrated Lead Discovery Platform, enabling screening of large volumes of compounds against clients’ target assays. BioTrove’s mass spectrometry-based RapidFire platform, which enables label-free high-throughput screening using biological substrates, will be used to identify active compounds within chemical libraries.

“The synergistic combination of OSI’s Lead Discovery Platform with BioTrove’s RapidFire screening technology provides an innovative solution to early drug discovery, opening up a wide array of new targets for the biotechnology industry,” said David Ghesquiere, Vice President, Corporate and Business Development, OSI Pharmaceuticals, Inc.

Financial terms were not disclosed.

Advertisement